Bioatla Inc (BCAB) Stock Price, Quote & News

Company Profile

BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC to treat melanoma and squamous cell carcinoma o...

Industry: Biotechnology

Sector: Healthcare

Phone: 858 558 0708

Fax: 858 558 0709

Website: www.bioatla.com

Address:

11085 Torreyana Road, San Diego, United States

MEGABIO Feb. 4 at 5:22 PM

$BCAB Since I bought in yesterday, I'm already up almost 15%. What a great decision! And it looks like it has a long way to go. I wasn't familiar with this company, but I was surprised by the sharp drop and didn't quite understand why. It seems the market anticipates things, and there was a risk of delisting from the Nasdaq, but that's been sorted out. So, it will gradually rise, and any good news when Phase 3 begins will be positive catalysts. I hope I'm right.

1 · Reply

BIOCARP Feb. 4 at 4:53 PM

$BCAB It has a lot of potential. Target price published on January 13th: $4. An amazing pipeline. $40 in funding for Phase 3... It's going to have four times more cash than its current market capitalization! Phase 3 secured with very promising results after Phase 2...

0 · Reply

BIOCARP Feb. 4 at 3:36 PM

$BCAB

0 · Reply

biovaluable Feb. 4 at 2:34 PM

$BCAB short selling is starting.

0 · Reply

biovaluable Feb. 4 at 2:30 PM

$BCAB start pump & dump. Go below

0 · Reply

biovaluable Feb. 4 at 2:27 PM

$BCAB delisting notice maybe announced at friday. (4 business day)

1 · Reply

jackabe Feb. 4 at 2:27 PM

$BCAB what a fxcking clown I'm trading it trying to make a few quid like the rest of the mkt is and have made no secrete to the fact.Also that was is actually factual the great china conspiracy has been out in the open since the ipo Those are the facts coco Tossers everywhere

1 · Reply

biovaluable Feb. 4 at 2:26 PM

$BCAB massive short is comming

0 · Reply

biovaluable Feb. 4 at 2:25 PM

$BCAB this ID, Account created today. @biocarp second ID

0 · Reply

MEGABIO Feb. 4 at 2:24 PM

$BCAB I've studied the company. Their products are promising. One very advanced one, OZ-V, is in Phase 3 trials. They've invested money in its development; whoever invested it isn't stupid and knows what they're getting into... and if they're risking $40 million, it's for a reason. Financially, it's doing terribly... but like all biotech companies, it takes off until something big happens and the stock takes off. I think it will be a good year. I bought a significant position yesterday. I'll be here for a few months.

0 · Reply

BioAtla and GATC Health Announce a $40 Million Special Purpose Vehicle (SPV) Transaction to Advance Ozuriftamab Vedotin (Oz-V) into a Registrational Trial for 2L+ Oropharyngeal Squamous Cell Carcinoma (OPSCC)

Nov 21, 2025, 12:25 AM EST - 2 months ago

BioAtla Enters into Agreements for up to $22.5 Million Flexible Financing

Nov 13, 2025, 6:51 PM EST - 2 months ago

BioAtla, Inc. (BCAB) Q3 2025 Earnings Call Transcript

Nov 13, 2025, 4:05 PM EST - 2 months ago

BioAtla Reports Third Quarter 2025 Financial Results and Highlights Recent Progress

$BioAtla's Mecbotamab Vedotin (Mec-V), an AXL-targeting ADC, Demonstrates a Median Overall Survival (OS) of 21.5 months in Subtypes of Refractory Soft Tissue Sarcomas$

Nov 7, 2025, 9:00 AM EST - 3 months ago

BioAtla's Mecbotamab Vedotin (Mec-V), an AXL-targeting ADC, Demonstrates a Median Overall Survival (OS) of 21.5 months in Subtypes of Refractory Soft Tissue Sarcomas

Nov 5, 2025, 8:00 AM EST - 3 months ago

BioAtla to Announce Third Quarter 2025 Financial Results and Provide Business Highlights on November 13, 2025

Oct 23, 2025, 8:00 AM EDT - 3 months ago

BioAtla Presents Compelling Mechanistic Rationale for Targeting ROR2 with Ozuriftamab Vedotin (Oz-V) in Oropharyngeal Squamous Cell Carcinoma (OPSCC) at the Annual Conference of the International Papillomavirus Society

$BioAtla Presents Promising Interim Data from its Phase 1 Trial with BA3182 in Patients with Treatment Refractory Metastatic Adenocarcinoma at ESMO 2025$

Oct 20, 2025, 8:00 AM EDT - 3 months ago

BioAtla Presents Promising Interim Data from its Phase 1 Trial with BA3182 in Patients with Treatment Refractory Metastatic Adenocarcinoma at ESMO 2025

Oct 3, 2025, 9:00 AM EDT - 4 months ago

BioAtla to Present Clinical Data for Mecbotamab Vedotin (BA3011) in Soft Tissue Sarcoma at SITC 2025

Sep 8, 2025, 8:00 AM EDT - 5 months ago

BioAtla Announces Regulatory Update on Clinical Development Plan for Ozuriftamab Vedotin in Oropharyngeal Squamous Cell Carcinoma (OPSCC) Following Productive Type B (End of Phase 2) Meeting with FDA

Aug 9, 2025, 2:43 AM EDT - 6 months ago

BioAtla, Inc. (BCAB) Q2 2025 Earnings Call Transcript

Aug 7, 2025, 4:05 PM EDT - 6 months ago

BioAtla Reports Second Quarter 2025 Financial Results and Highlights Recent Progress

Aug 4, 2025, 8:00 AM EDT - 6 months ago

BioAtla to Announce Second Quarter 2025 Financial Results and Provide Business Highlights on August 7, 2025

Jul 17, 2025, 8:00 AM EDT - 7 months ago

BioAtla Announces Upcoming Oral Presentation at the 2025 European Society for Medical Oncology (ESMO) TAT Asia Meeting

$BioAtla Presents Data from Ongoing Dose Escalation of BA3182, Dual-Conditionally Binding EpCAM x CD3 Bispecific T-cell Engager, in Patients with Treatment Refractory Metastatic Adenocarcinoma at the 2025 European Society for Medical Oncology (ESMO) Gastrointestinal Cancers Congress$

Jul 3, 2025, 8:00 AM EDT - 7 months ago

BioAtla Presents Data from Ongoing Dose Escalation of BA3182, Dual-Conditionally Binding EpCAM x CD3 Bispecific T-cell Engager, in Patients with Treatment Refractory Metastatic Adenocarcinoma at the 2025 European Society for Medical Oncology (ESMO) Gastrointestinal Cancers Congress

Jun 2, 2025, 8:00 AM EDT - 8 months ago

BioAtla Presents Phase 2 Ozuriftamab Vedotin (Oz-V) Clinical Trial Data Demonstrating Compelling Antitumor Activity in HPV-Associated Oropharyngeal Squamous Cell Carcinoma (HPV+ OPSCC) at the 1.8 mg/kg Q2W dosing regimen

May 6, 2025, 5:55 PM EDT - 9 months ago

BioAtla, Inc. (BCAB) Q1 2025 Earnings Call Transcript

May 6, 2025, 4:05 PM EDT - 9 months ago

BioAtla Reports First Quarter 2025 Financial Results and Highlights Recent Progress

Apr 30, 2025, 8:00 AM EDT - 10 months ago

BioAtla to Participate in the Citizens Life Sciences Conference

Apr 29, 2025, 8:00 AM EDT - 10 months ago

BioAtla to Announce First Quarter 2025 Financial Results and Provide Business Highlights on May 6, 2025

Apr 24, 2025, 8:00 AM EDT - 10 months ago

BioAtla Announces Poster Presentations at the 2025 American Association for Cancer Research (AACR) Annual Meeting

Apr 23, 2025, 10:05 AM EDT - 10 months ago

BioAtla Announces Upcoming Poster Presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

Mar 27, 2025, 6:18 PM EDT - 11 months ago

BioAtla, Inc. (BCAB) Q4 2024 Earnings Call Transcript

Mar 27, 2025, 5:05 PM EDT - 11 months ago

BioAtla Cuts 30% of Jobs in Restructuring Effort

Mar 27, 2025, 4:05 PM EDT - 11 months ago

BioAtla Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Progress

Mar 20, 2025, 8:00 AM EDT - 11 months ago

BioAtla Announces Two Poster Presentations at Upcoming Medical Meetings

Mar 19, 2025, 8:00 AM EDT - 11 months ago

BioAtla to Announce Fourth Quarter and Full-Year 2024 Financial Results and Provide Business Highlights on March 27, 2025

Mar 4, 2025, 7:34 AM EST - 1 year ago

AXL Inhibitors Pipeline Research Report 2025: Features Insights on 16+ Companies and 20+ Pipeline Drugs, Including Cabozantinib (Exelixis/Ipsen), BA 3011 (BioAtla) & TP-0903 (Sumitomo Dainippon Pharma Oncology)

Dec 20, 2024, 9:00 AM EST - 1 year ago

BioAtla, Inc. Announces Registered Direct Offering to Advance Two Mid-Stage Clinical Programs to Key Inflection Points

Dec 16, 2024, 8:00 AM EST - 1 year ago

BioAtla Presented Data Characterizing Mutated KRAS Genotype and Clinical Outcomes in Patients with Advanced NSCLC Treated with Mecbotamab Vedotin (Mec-V), a CAB-AXL-ADC, at the IASLC 2024 Hot Topic in Basic & Translational Science Meeting

Dec 10, 2024, 8:00 AM EST - 1 year ago

BioAtla Announces Upcoming Poster Presentation at the IASLC 2024 Hot Topic in Basic & Translational Science Meeting

Nov 9, 2024, 8:53 AM EST - 1 year ago

BioAtla, Inc. (BCAB) Q3 2024 Earnings Call Transcript

Oct 8, 2024, 6:12 AM EDT - 1 year ago

BioAtla's FDA Fast-Tracked Drug Candidate Boosts Its Oncology Prospects, Speculative Buy

Oct 7, 2024, 11:29 AM EDT - 1 year ago

BioAtla: Numerous Catalysts Coming In Q4

Oct 4, 2024, 9:05 AM EDT - 1 year ago

BioAtla Announces Upcoming Poster Presentation at the 39th Society for Immunotherapy of Cancer Annual Meeting

Oct 1, 2024, 8:00 AM EDT - 1 year ago

BioAtla Announces Upcoming Oral Presentation at the Society for Melanoma Research 21st International Congress

Sep 23, 2024, 7:30 AM EDT - 1 year ago

BioAtla and Context Therapeutics Announce Exclusive Worldwide License Agreement to Develop and Commercialize BA3362, a Nectin-4 x CD3 T Cell Engaging Antibody

Aug 11, 2024, 1:32 AM EDT - 1 year ago

BioAtla, Inc. (BCAB) Q2 2024 Earnings Call Transcript

Jul 25, 2024, 5:39 PM EDT - 1 year ago

BioAtla Highlighted Clinical Program and Pipeline Updates at Virtual R&D Day

May 29, 2024, 8:00 AM EDT - 1 year ago

BioAtla to Participate in the Jefferies Global Healthcare Conference

May 23, 2024, 5:05 PM EDT - 1 year ago

BioAtla Presenting Phase 1 Evalstotug Clinical Trial Data Demonstrating Clinical Benefit at the Upcoming 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

May 14, 2024, 8:35 PM EDT - 1 year ago

BioAtla, Inc. (BCAB) Q1 2024 Earnings Call Transcript

May 14, 2024, 4:05 PM EDT - 1 year ago

BioAtla Reports First Quarter 2024 Financial Results and Highlights Recent Progress

May 8, 2024, 8:00 AM EDT - 1 year ago

BioAtla to Participate in the Citizens JMP Life Sciences Conference

May 7, 2024, 8:00 AM EDT - 1 year ago

BioAtla to Announce First Quarter 2024 Financial Results and Provide Business Highlights on May 14, 2024

May 6, 2024, 8:00 AM EDT - 1 year ago

BioAtla Announces FDA Clearance of Investigational New Drug Application for BA3361, a CAB-Nectin-4 Antibody Drug Conjugate for the Treatment of Multiple Tumors

May 2, 2024, 10:03 AM EDT - 1 year ago

BioAtla: A Buried ADC Concern Gets Some New Life In 2024

Apr 24, 2024, 4:35 PM EDT - 1 year ago

BioAtla Announces Upcoming Poster Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Mar 26, 2024, 7:21 PM EDT - 2 years ago

BioAtla, Inc. (BCAB) Q4 2023 Earnings Call Transcript

Mar 26, 2024, 4:01 PM EDT - 2 years ago

BioAtla Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Progress

MEGABIO Feb. 4 at 5:22 PM

1 · Reply

BIOCARP Feb. 4 at 4:53 PM

0 · Reply

BIOCARP Feb. 4 at 3:36 PM

$BCAB

0 · Reply

biovaluable Feb. 4 at 2:34 PM

$BCAB short selling is starting.

0 · Reply

biovaluable Feb. 4 at 2:30 PM

$BCAB start pump & dump. Go below

0 · Reply

biovaluable Feb. 4 at 2:27 PM

$BCAB delisting notice maybe announced at friday. (4 business day)

1 · Reply

jackabe Feb. 4 at 2:27 PM

1 · Reply

biovaluable Feb. 4 at 2:26 PM

$BCAB massive short is comming

0 · Reply

biovaluable Feb. 4 at 2:25 PM

$BCAB this ID, Account created today. @biocarp second ID

0 · Reply

MEGABIO Feb. 4 at 2:24 PM

0 · Reply

MEGABIO Feb. 4 at 2:21 PM

$BCAB This is what ultimately matters... the studies of professional investors.

0 · Reply

MEGABIO Feb. 4 at 2:20 PM

$BCAB I think some people are trying to drive the stock down because they're covert short sellers. If you're not invested and you think it's a terrible stock, why all the fuss as if your life depended on it? Please don't pollute the forum.

0 · Reply

biovaluable Feb. 4 at 1:29 PM

$BCAB lol. . .short...

0 · Reply

biovaluable Feb. 4 at 12:44 PM

$BCAB will move like $HOOK which delisted last year.

0 · Reply

sionist Feb. 4 at 12:35 PM

$BCAB pump & dump

0 · Reply

sionist Feb. 4 at 12:34 PM

$BCAB pump & dump

0 · Reply

sionist Feb. 4 at 12:34 PM

$BCAB pump & dump

0 · Reply

sionist Feb. 4 at 12:34 PM

$BCAB pump & dump

0 · Reply

sionist Feb. 4 at 12:34 PM

$BCAB amazing

0 · Reply

sionist Feb. 4 at 12:33 PM

$BCAB fact

0 · Reply

sionist Feb. 4 at 12:33 PM

$BCAB fact

0 · Reply

sionist Feb. 4 at 12:33 PM

$BCAB fact

0 · Reply

Market Cap	17.07M
Revenue (ttm)	11.00M
Net Income (ttm)	-69.78M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-634.36%
Debt to Equity Ratio	0.00

Volume	5,959,800
Avg Vol	2,364,488
Day's Range	N/A - N/A
Shares Out	63.46M
Stochastic %K	20%
Beta	1.04
Analysts	Sell
Price Target	$10.00